Dako Enters into an Additional Collaboration with Amgen
News Feb 28, 2012
Dako has announced that it has entered into a new collaboration agreement with Amgen Inc. on the development of a diagnostic test for an Amgen cancer drug candidate in clinical development.
“It is Dako’s mission to fight cancer. Hence, we are pleased to be chosen as Amgen’s partner once again for the development of companion diagnostics linked to Amgen’s investigational targeted therapies,” says Lars Holmkvist, Dako’s chief executive officer.
In January 2012, Dako announced a collaboration agreement with Amgen Inc. introducing a new business model which supports the concurrent development of drug and diagnostics for a rare but deadly cancer - something that up to this point has been difficult to achieve in the industry.
“This new collaboration with Amgen underlines Dako’s commitment to advance personalized medicine in cancer treatment as the selection of patients most likely to benefit from a specific treatment will increase the probability of therapeutic success for cancer patients suffering," Lars Holmkvist adds.
Today’s news comes on the heels of several pharmDx™ collaborative agreements recently announced by Dako.
The demand for personalized medicine is increasing with the recognition that it may provide a way to improve patient care and manage healthcare costs by targeting treatments to individuals more likely to benefit from specific therapies.
Allergic Responses May Protect Against Skin CancerNews
The components of the immune system that trigger allergic reactions may also help protect the skin against cancer, suggest new findings.READ MORE
Potential Treatment for Rare Inherited CancersNews
Studying two rare inherited cancer syndromes, scientists have found the cancers are driven by a breakdown in how cells repair their DNA. The discovery suggests a promising strategy for treatment with drugs recently approved for other forms of cancer, said the researchers.READ MORE